sulfaphenazole has been researched along with Coronary Artery Disease in 1 studies
Sulfaphenazole: A sulfonilamide anti-infective agent.
sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of sulfaphenazole, a selective inhibitor of CYP 2C9, on endothelium-dependent (acetylcholine) and endothelium-independent (sodium nitroprusside, SNP) FBF responses were measured by venous occlusion plethysmography in 5 healthy subjects and in 16 patients with angiographically documented stable coronary artery disease." | 5.11 | Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. ( Breuer, S; Busse, R; Dimmeler, S; Fichtlscherer, S; Fleming, I; Zeiher, AM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fichtlscherer, S | 1 |
| Dimmeler, S | 1 |
| Breuer, S | 1 |
| Busse, R | 1 |
| Zeiher, AM | 1 |
| Fleming, I | 1 |
1 trial available for sulfaphenazole and Coronary Artery Disease
| Article | Year |
|---|---|
Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.
Topics: Acetylcholine; Adult; Aryl Hydrocarbon Hydroxylases; Ascorbic Acid; Blood Proteins; Coronary Artery | 2004 |